{"id":19283,"date":"2015-10-03T19:41:22","date_gmt":"2015-10-03T16:41:22","guid":{"rendered":"https:\/\/zeolife.gr\/clinoptilolite-enhancement-artificially-enhanced-aluminosilicate-zeolite-reduces-symptoms-associated-with-endoscopically-negative-gastro-oesophageal-reflux-disease-and-non-steroidal-anti-inflammatory\/"},"modified":"2015-10-03T19:41:22","modified_gmt":"2015-10-03T16:41:22","slug":"clinoptilolite-enhancement-artificially-enhanced-aluminosilicate-zeolite-reduces-symptoms-associated-with-endoscopically-negative-gastro-oesophageal-reflux-disease-and-non-steroidal-anti-inflammatory","status":"publish","type":"post","link":"https:\/\/zeolife.gr\/en\/clinoptilolite-enhancement-artificially-enhanced-aluminosilicate-zeolite-reduces-symptoms-associated-with-endoscopically-negative-gastro-oesophageal-reflux-disease-and-non-steroidal-anti-inflammatory\/","title":{"rendered":"Clinoptilolite enhancement: artificially enhanced aluminosilicate zeolite reduces symptoms associated with endoscopically negative gastro-oesophageal reflux disease and non-steroidal anti-inflammatory drugsinduced by gastritis (Potentiated clinoptilolite: artificially enhanced aluminosilicate reduces symptoms associated with endoscopically negative gastro-oesophageal reflux disease and non-steroidal anti-inflammatory drug-induced gastritis)"},"content":{"rendered":"
\"Clinoptilolite
(A) Normal stomach lining of volunteer after first endoscopic evaluation; (B) endoscopic image taken after the study period.<\/figcaption><\/figure>\n

Wilna Potgieter, Caroline Selma Samuels, and Jacques Ren\u00e8 Snyman<\/p>\n

Department of Pharmacology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, Gauteng, South Africa<\/p>\n

Correspondence: Jacques Ren\u00e8 Snyman, Department of Pharmacology, School of Medicine, Faculty of Health Sciences, University of Pretoria, PO Box 167, Cornwall Hill Estate, Irene, Pretoria, 0178, South Africa, Tel +27 12 673 8600, Email az.oc.vamred@seuqcaj<\/a><\/p>\n

Copyright \u00a9 2014 Potgieter et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution \u2013 Non Commercial (unported, v3.0) License<\/p>\n

The full terms of the License are available at http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/<\/a>. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.<\/p>\n

Abstract<\/h2>\n

Purpose<\/h3>\n

The cation exchanger, a potentiated clinoptilolite (Absorbatox\u2122 2.4D), is a synthetically enhanced aluminosilicate. The aim of this study was to evaluate the possible benefits of a potentiated clinoptilolite as a gastroprotective agent in reducing the severity of clinical symptoms and signs associated with 1) endoscopically negative gastroesophageal reflux disease (ENGORD) and 2) nonsteroidal anti-inflammatory drug (NSAID) medication.<\/p>\n

Methods and patients<\/h3>\n

Two randomized, double-blind, placebo-controlled, pilot studies, the ENGORD and NSAID studies, were conducted. After initial negative gastroscopy, a total of 25 patients suffering from ENGORD were randomized to receive either placebo capsules or 750 mg Absorbatox twice daily for 14 days. The NSAID study recruited 23 healthy patients who received orally either 1,500 mg Absorbatox or placebo three times daily, plus 500 mg naproxen twice daily. Patients underwent gastroscopic evaluation of their stomach linings prior to and on day 14 of the study. Gastric biopsies were obtained and evaluated via the upgraded Sydney system, whereas visible gastric events and status of the gastric mucosa were evaluated via a 0\u20133 rating scale. During both studies, patients recorded gastric symptoms in a daily symptom diary.<\/p>\n

Results<\/h3>\n

In the ENGORD study, patients who received the potentiated clinoptilolite reported a significant reduction (P\u22640.05) in severity of symptoms including reduction in heartburn (44%), discomfort (54%), and pain (56%). Symptom-free days improved by 41% compared to the group who received placebo (not significant). This was over and above the benefits seen with the proton pump inhibitor. In the NSAID study, the reduction in gastric symptom severity was echoed in the group who received the potentiated clinoptilolite. Treatment with the potentiated clinoptilolite resulted in significant prevention (P\u22640.05) of mucosal erosion severity as graded by the gastroenterologist.<\/p>\n

Conclusion<\/h3>\n

Absorbatox is a nonabsorbable aluminosilicate with potential gastroprotective benefits as it protected against ENGORD symptoms and NSAID-induced gastric events. The exact mechanism of action is not clear but may be due to its binding to hydrogen ions and biologically active amines and nitrates.<\/p>\n